Jane Street Group LLC Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Jane Street Group LLC lifted its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 1.1% in the third quarter, Holdings Channel reports. The firm owned 144,575 shares of the biopharmaceutical company’s stock after buying an additional 1,640 shares during the period. Jane Street Group LLC’s holdings in Theravance Biopharma were worth $1,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Theravance Biopharma during the 3rd quarter valued at $60,000. China Universal Asset Management Co. Ltd. grew its position in shares of Theravance Biopharma by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,696 shares in the last quarter. Ballentine Partners LLC purchased a new position in shares of Theravance Biopharma during the third quarter valued at $104,000. Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma in the second quarter valued at about $108,000. Finally, XTX Topco Ltd purchased a new stake in Theravance Biopharma in the second quarter worth about $129,000. Institutional investors own 99.10% of the company’s stock.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Trading Down 2.7 %

Shares of NASDAQ:TBPH opened at $9.59 on Monday. The company has a market capitalization of $471.58 million, a PE ratio of -9.50 and a beta of 0.23. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $11.71. The business’s fifty day simple moving average is $9.34 and its 200-day simple moving average is $8.85.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same quarter last year, the firm earned ($0.17) EPS. Research analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.